To the full analysis
AMN Healthcare Services stock: growth
AMNAMN Healthcare Services reported $2.73B in revenue for fiscal 2025, down 8.5% on the prior year, up 2.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5%
per year from 2006 to 2025, per share 4.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
9.1%
per year from 2006 to 2025, per share 8.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.7% | 6.4% | 5.0% |
| Revenue per share | 7.0% | 8.7% | 4.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 1.4% | 22.8% | 9.1% |
| Free cash flow per share | 5.7% | 25.4% | 8.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.08B | $35.09M | $44.82M |
| 2007 | $1.16B | $36.53M | $70.49M |
| 2008 | $1.22B | $34.36M | $54.9M |
| 2009 | $759.79M | −$122.18M | $94.94M |
| 2010 | $689.22M | −$51.99M | $3.92M |
| 2011 | $887.47M | −$26.27M | $14.66M |
| 2012 | $953.95M | $17.14M | $55.04M |
| 2013 | $1.01B | $32.93M | $49.59M |
| 2014 | $1.04B | $33.22M | $8.54M |
| 2015 | $1.46B | $81.89M | $30.04M |
| 2016 | $1.9B | $105.84M | $109.9M |
| 2017 | $1.99B | $132.56M | $88.73M |
| 2018 | $2.14B | $141.74M | $190.61M |
| 2019 | $2.22B | $113.99M | $188.4M |
| 2020 | $2.39B | $70.67M | $217.72M |
| 2021 | $3.98B | $327.39M | $251.69M |
| 2022 | $5.24B | $444.05M | $572.81M |
| 2023 | $3.79B | $210.68M | $268.48M |
| 2024 | $2.98B | −$146.98M | $239.53M |
| 2025 | $2.73B | −$95.7M | $233.83M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.